Watch More Highlights
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses a subgroup analysis of elderly patients enrolled in the phase III POLARIX study. In POLARIX, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a similar safety profile in patients aged 18 to 80 years with previously untreated diffuse large B-cell lymphoma (DLBCL). In this subgroup analysis, Pola-R-CHP and R-CHOP demonstrated similar safety profiles in patients aged ≥ 70 years with previously untreated DLBCL (Abstract 7518).